Zc(=o)oy, Wherein Z Is An Acyclic Radical Bonded To The C=o By A Carbon And Y Is An Organic Radical Bonded To The Oxygen By A Carbon Patents (Class 514/546)
  • Publication number: 20130324597
    Abstract: This invention pertains to an anti-microbial, in particular anti-bacterial, more particularly against Gram?bacteria, and/or anti-fungal composition comprising as active blend trans-cinnamaldehyde and a potentiating agent, and to the potentiating agent. In particular this composition is intended for preventing and/or treating microbial infection in an animal.
    Type: Application
    Filed: December 9, 2011
    Publication date: December 5, 2013
    Applicant: SEPTEOS
    Inventor: Nicolas Tesse
  • Publication number: 20130324606
    Abstract: Provided herein, inter alia, are prodrugs of bimatoprost, methods of using the same and compositions including the same.
    Type: Application
    Filed: February 13, 2012
    Publication date: December 5, 2013
    Applicant: ALLERGAN, INC.
    Inventors: David F. Woodward, Jenny W. Wang, Neil J. Poloso, Todd S. Gac, Robert M. Burk, Michael E. Garst
  • Patent number: 8598231
    Abstract: Biodegradable flavoring agent compositions comprising 1,3-propanediol are provided, and the 1,3-propanediol in the composition is biologically derived. The compositions exhibit a lower anthropogenic CO2 emission profile. Also provided are biodegradable flavoring agent compositions comprising an ester of 1,3-propanediol. In these compositions, the ester can have at least 3% biobased carbon.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 3, 2013
    Assignee: DuPont Tate & Lyle Bio Products Company, LLC
    Inventors: Gyorgyi Fenyvesi, Melissa Joerger, Robert Miller, Ann Wehner
  • Patent number: 8597668
    Abstract: The present invention relates to a composition comprising: (a) at least one alkoxylated polyamine; (b) at least one organic acid chosen from alkyl acids, alkoxylated monoacids, and mixtures thereof; (c) at least one lipophilic compound; and (d) at least one solvent comprising water. Such a composition is clear in appearance, and stable. The present invention also relates to a method of making such a clear composition, and to a method of cosmetic treatment of a keratinous substrate using such a composition.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: December 3, 2013
    Assignee: L'Oreal
    Inventors: Nghi Van Nguyen, Sawa Hashimoto, David W. Cannell
  • Patent number: 8586064
    Abstract: The treatment of humans or other mammals for eczema and/or psoriasis using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 19, 2013
    Assignee: Lypanosys Pte Limited
    Inventors: Timothy David Meakin, Dianne Cadwallader, Craig Leonard Heatley
  • Patent number: 8586632
    Abstract: The invention provides oleocanthal analogs and methods of using oleocanthals in various formulations including, food additives; pharmaceuticals; cosmetics; animal repellants; and discovery tools for mammalian irritation receptor genes, gene products, alleles, splice variants, alternate transcripts and the like.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: November 19, 2013
    Assignees: Monell Chemical Senses Center, The Trustees of The University of Pennsylvania
    Inventors: Catherine Peyrot Des Gachons, Jeffrey B. Sperry, Bruce Bryant, Paul A. S. Breslin, Amos B. Smith, III, Gary K. Beauchamp
  • Publication number: 20130302480
    Abstract: Antimicrobial compositions comprising one or more compound components generally recognized as safe for human consumption, and related methods of use, such compositions and methods as can be employed in a wide range of agricultural, industrial, building, pharmaceutical and/or personal care products and, applications.
    Type: Application
    Filed: March 15, 2013
    Publication date: November 14, 2013
    Inventors: Niranjan Ramanlal Gandhi, Victoria Palmer Skebba, Gary A. Strobel
  • Publication number: 20130303473
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 14, 2013
    Applicant: NOVALIQ GmbH
    Inventor: Clive G. Wilson
  • Patent number: 8580775
    Abstract: The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. The invention furthermore relates to specific substances.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: November 12, 2013
    Assignee: Cognis IP Management GmbH
    Inventors: Thomas Markert, Philippe Moussou, Louis Danoux, Andreas Rathjens
  • Publication number: 20130295196
    Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 7, 2013
    Applicant: ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Inventor: Eric Konofal
  • Publication number: 20130296423
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Application
    Filed: July 2, 2013
    Publication date: November 7, 2013
    Inventors: Hans-Jürgen MIKA, Christoph ARTH, Michael KOMENDA, Fatima BICANE, Kerstin PAULUS, Meike IRNGARTINGER, Hans LINDNER
  • Publication number: 20130296323
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.
    Type: Application
    Filed: February 27, 2013
    Publication date: November 7, 2013
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
  • Patent number: 8574609
    Abstract: Broad spectrum disinfecting and microbicidal compositions of biodegradable and environmentally friendly compositions containing esters formed from fatty organic alcohols and fatty carboxylic acids. These compositions display activities against the most resistant microbial forms including bacterial spores. The preparations can be used in health care, food processing, personal care and other industries where the use of harsh oxidizing chemicals is undesirable.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: November 5, 2013
    Inventor: John Alex Lopes
  • Publication number: 20130289059
    Abstract: The present invention generally relates to the improvement of tissue health by increasing local blood flow. In some aspects of the invention, increased local blood flow is effected by the transdermal delivery of the nitric oxide precursor L-arginine and/or its derivatives alone, or optionally in conjunction with an adjunct such as theophylline. The transdermal delivery is effected, in certain embodiments through the means of a hostile biophysical environment, such as that created by a high ionic strength environment. Various pathological states caused by, or occurring in conjunction with, insufficient blood flow, can be treated using the systems and methods of the invention as described herein. In other embodiments, increased blood flow using the systems and methods of the invention may result in enhanced healing, for example, through greater availability of the constituents of the blood.
    Type: Application
    Filed: April 10, 2013
    Publication date: October 31, 2013
    Inventor: Eric T. Fossel
  • Publication number: 20130289006
    Abstract: Compositions are disclosed that contain an effective hyperpigmentation-treating active agent and a pharmaceutically-acceptable carrier or vehicle. Methods of using the compositions to treat hyperpigmentation are also disclosed.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 31, 2013
    Inventor: Bryan B. Fuller
  • Publication number: 20130287847
    Abstract: The present invention relates to a solid molecular dispersion of fesoterodine hydrogen fumarate and a polymeric binder. The invention also relates to an inert core bead or particle which is coated with said solid molecular dispersion and to pharmaceutical formulations comprising such coated beads or particles.
    Type: Application
    Filed: January 17, 2012
    Publication date: October 31, 2013
    Inventors: Roland Bodmeier, Alan Francis Carmody, Mesut Ciper, Anne Therese Gustaaf De Paepe, John Mark Heimlich, Martin Korber, Mathias Walther, Neil Feeder
  • Patent number: 8569365
    Abstract: The invention features methods of inhibiting the growth of, or killing, fungal and certain bacterial microorganisms with one or more of a family of glycerol-based compounds.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: October 29, 2013
    Assignee: Regents of the University of Minnesota
    Inventors: Patrick M. Schlievert, Marnie L. Peterson
  • Publication number: 20130281394
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: October 24, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
  • Publication number: 20130281454
    Abstract: Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 24, 2013
    Applicant: ALLERGAN, INC.
    Inventors: RHETT M. SCHIFFMAN, JUNE CHEN
  • Publication number: 20130280195
    Abstract: Compositions containing an effective dermatological disease-treating or dermatological condition-treating active agent and a pharmaceutically-acceptable carrier or vehicle are disclosed. Methods of using the compositions are also disclosed.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 24, 2013
    Inventor: Bryan B. Fuller
  • Publication number: 20130281411
    Abstract: Compositions are disclosed that contain an effective inflammatory-dermatological disease-treating or condition-treating active agent and a pharmaceutically-acceptable carrier or vehicle. Methods of using the compositions to treat a subject's skin are also disclosed.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 24, 2013
    Inventor: Bryan B. Fuller
  • Publication number: 20130281387
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
    Type: Application
    Filed: October 18, 2011
    Publication date: October 24, 2013
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
  • Publication number: 20130274231
    Abstract: Compositions containing an effective dermatological disease-treating or dermatological condition-treating active agent and a pharmaceutically-acceptable carrier or vehicle are disclosed.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 17, 2013
    Inventor: Bryan B. Fuller
  • Publication number: 20130267592
    Abstract: Pro-drugs of 1-(2-halo-biphenyl-4-yl)alkanecarboxylic acids are useful for preventing and/or treating neurodegenerative diseases, improving cognitive function and treating cognitive impairment.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 10, 2013
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Bruno Pietro IMBIMBO, Luca Raveglia
  • Publication number: 20130261133
    Abstract: The compounds of the invention exhibit antiprotozoal, antimicrobial, and anticancer properties that are useful for the treatment or prevention of infections or cancer in a patient (e.g., a human). For example, the compounds and methods described herein can be used for the treatment or prevention of protozoal infections such as leishmaniasis, malaria, and trypanosoma infections, bacterial infections such as S. aureus and C. albicans, and cancers such as breast, colon, lung, or prostate cancer. The invention further provides methods of synthesizing such compounds as well as kits useful for administering the compounds.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 3, 2013
    Applicant: The University of Montana
    Inventors: John Howard Hoody, David Brian Bolstad
  • Patent number: 8541467
    Abstract: The present invention refers to the use of the compound of Formula (I?) or pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of hematological dyscrasias, including myelodisplastic syndromes (MDSs) and for improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy. In addition, it relates to the use of a compound of formula (I?) for the treatment and/or prophylaxis of cancer of an organ.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: September 24, 2013
    Assignee: Action Medicines, S.L.
    Inventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Morgan, Javier Angulo Frutos, Rosa Maria Lozano Puerto, Antonio Romero Garrido, Serafin Valverde Lopez
  • Publication number: 20130245053
    Abstract: The present disclosure relates to pesticidal compositions and to methods for controlling pests such as insects and other arthropods. More particularly, the disclosure relates to a pesticidal compositions containing mineral oil and one or more additional components which, when used in combination, act synergistically to control insect and pest populations.
    Type: Application
    Filed: May 8, 2013
    Publication date: September 19, 2013
    Inventor: Steven R. Sims
  • Patent number: 8535696
    Abstract: The treatment of humans or other mammals for eczema and/or psoriasis using dosage forms or compositions that include cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: September 17, 2013
    Assignee: Lypanosys Pte Limited
    Inventors: Timothy David Meakin, Dianne Cadwallader, Craig Leonard Heatley
  • Publication number: 20130236544
    Abstract: The present invention relates to stable pharmaceutical compositions comprising fesoterodine or a pharmaceutically acceptable salt thereof. In particular, the invention relates to pharmaceutical compositions of fesoterodine or a pharmaceutically acceptable salt thereof and a stabilizer. The invention also relates to processes for making such compositions and the methods of using such compositions.
    Type: Application
    Filed: March 6, 2013
    Publication date: September 12, 2013
    Applicant: DR. REDDY'S LABORATORIES LTD.
    Inventors: Harshal Prabhakar Bhagwatwar, Venkateswarlu Vobalaboina, Pradip Kumar Ghosh, Srinivasa Rao Gella, Ramakoti Reddy Ch, Sandip Shivaji Chavhan, Pratit Premchand Agrawal
  • Publication number: 20130216488
    Abstract: The present disclosure relates to extracts from Persea sp. (avocado) enriched in bioactive compounds which can be used as antimicrobial, antibacterial or spore germination inhibiting agents, the process for obtaining the extracts, acetogenins and isolated molecules and methods for using the extracts enriched in bioactive compounds for providing antimicrobial, antibacterial or spore germination inhibiting effect.
    Type: Application
    Filed: February 8, 2013
    Publication date: August 22, 2013
    Applicants: AVOMEX, INC, INSTITUTO TECNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY
    Inventors: INSTITUTO TECNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY, AVOMEX, INC.
  • Patent number: 8513302
    Abstract: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”). Optionally, a cis-epoxyeicosantrienoic acid (“EET”) can be administered with the sEH inhibitor. The invention further provides for using EETs in conjunction with one or more sEH inhibitors to reduce hypertension, and for compositions of EETs coated with a material insoluble in an acid of pH 3 but soluble in a solution with a pH of 7.4 or higher.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: August 20, 2013
    Assignee: The Regents of the University of California
    Inventors: Bruce D. Hammock, Takaho Watanabe, Seung-Jin Ma, Susan E. Bennett, Judith S. Stern, Christophe Morisseau, In-Hae Kim
  • Patent number: 8512723
    Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including, in particular, an antimicrobial lipid component, such as a fatty acid ester, fatty ether, or alkoxide derivative thereof. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component. Such compositions provide effective topical antimicrobial activity and are accordingly useful in the treatment and/or prevention of conditions that are caused, or aggravated by, microorganisms (including viruses).
    Type: Grant
    Filed: September 8, 2004
    Date of Patent: August 20, 2013
    Assignee: 3M Innovative Properties Company
    Inventors: Matthew T. Scholz, Dianne L. Gibbs, John T. Capecchi, Jeffrey F. Andrews
  • Publication number: 20130202580
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, actinic keratosis.
    Type: Application
    Filed: February 14, 2013
    Publication date: August 8, 2013
    Applicant: AmDerma Pharmaceuticals, LLC
    Inventor: AmDerma Pharmaceuticals, LLC
  • Patent number: 8501200
    Abstract: Ophthalmic compositions that comprise 0.1 ppm to 2 ppm of poly(hexamethylene biguanide); and 0.005 wt. % to 0.3 wt. % of a PEG-glycerol ester of general formula I wherein R1 is a C3-C8alkyl and R2 is H or a C1-C4alkyl; and x+y+z has an average value from 8 to 30. The invention is also directed to the use of the ophthalmic compositions to clean and disinfect contact lenses, and in particular, soft, silicone hydrogel contact lenses.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: August 6, 2013
    Assignee: Bausch & Lomb Incorporated
    Inventor: Krista Fridman
  • Patent number: 8501723
    Abstract: The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: August 6, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Hans-Jürgen Mika, Christoph Arth, Michael Komenda, Fatima Bicane, Kerstin Paulus, Meike Irngartinger, Hans Lindner
  • Publication number: 20130197082
    Abstract: A process is described for the preparation of intermediates which can be used for preparation of agents for urinary incontinence therapy, specifically to 2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol and its prodrugs.
    Type: Application
    Filed: March 8, 2011
    Publication date: August 1, 2013
    Applicant: Lek Pharmaceuticals D.D.
    Inventor: Damjan Sterk
  • Patent number: 8497257
    Abstract: The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: July 30, 2013
    Assignee: Amderma Pharmaceuticals, LLC
    Inventor: Pedro Cuevas Sanchez
  • Patent number: 8492588
    Abstract: The present invention relates to benzyloxyanilide derivatives having the following structural formula: The compounds of the present invention are useful for the treatment and prevention of diseases and disorders which are affected by activation or modulation of potassium ion channels. One such condition is seizure disorders.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: July 23, 2013
    Assignee: Valeant Pharmaceuticals International
    Inventors: Jim Zhen Wu, Jean-Michel Vernier, Huanming Chen, Jianlan Song
  • Patent number: 8492367
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, rosacea.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: July 23, 2013
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sánchez, Guillermo Gimenez Gallego, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20130172355
    Abstract: The invention relates to a sulfur-containing compound and the preparation thereof. The invention also relates to the uses of the sulfur-containing compound in inhibiting inducible nitric oxide synthase and/or cyclooxygenase-2 and in treating the diseases associated with inducible nitric oxide synthase and/or cyclooxygenase-2. This invention also describes a series of chemical analogues of the said sulfur-containing compound and the preparation of these compounds.
    Type: Application
    Filed: February 6, 2013
    Publication date: July 4, 2013
    Applicant: NATIONAL SUN YAT-SEN UNIVERSITY
    Inventor: NATIONAL SUN YAT-SEN UNIVERSITY
  • Publication number: 20130171097
    Abstract: The present invention relates to a method for the prophylactic and/or therapeutic treatment of glucocorticoid induced osteoporosis comprising maintaining or restoring AP-1 activity or AP-1-mediated effects, for example by LIF treatment. The method may additionally comprise a method for the treatment of a medical condition associated with inflammation comprising inhibition of NF-KB activity, for example by glucocorticoid (GC) treatment. The present invention therefore also relates to a method for the treatment and/or prevention of glucocorticoid induced osteoporosis comprising the administration of an effective amount of LIF to a subject, preferably in combination with GC treatment.
    Type: Application
    Filed: December 7, 2012
    Publication date: July 4, 2013
    Applicant: Fritz-Lipmann-Institut E. V. Leibniz-Institut Fuer Altersforschung
    Inventor: Fritz-Lipmann-Institut E. V. Leibniz-Institut Fuer
  • Publication number: 20130172411
    Abstract: The present invention relates to stable pharmaceutical compositions comprising fesoterodine or salts thereof. In particular, the invention relates to pharmaceutical compositions of fesoterodine which does not contain sugar alcohols. The invention also relates to processes for making such compositions and use thereof in treating patients with urinary incontinence.
    Type: Application
    Filed: March 22, 2011
    Publication date: July 4, 2013
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Sunilendu Bhushan Roy, Sushrut Krishnaji Kulkarni, Pranav Jogani Dhirajbhai, Ajay Handa Kumar
  • Patent number: 8476318
    Abstract: The invention relates to polyethylene glycol esters and blends of the polyethylene glycol esters with polyethylene glycol ethers, together with in particular cosmetic and/or dermatological preparations containing them, methods for the production thereof and use thereof.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: July 2, 2013
    Assignee: Symrise AG
    Inventors: Gerhard Schmaus, Sabine Lange, Rolf Ohrmann, Martina Issleib
  • Patent number: 8470831
    Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: September 23, 2009
    Date of Patent: June 25, 2013
    Assignee: Cogenia SRL
    Inventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
  • Publication number: 20130156709
    Abstract: Environmentally friendly, low whitening compositions are described. The compositions have aromatic alcohols and esters with a melting point from about 20° C. to about 40° C. The compositions are substantially free of silicones and suitable to impart excellent sensory characteristics in the absence of whitening and when topically applied to the skin of a consumer.
    Type: Application
    Filed: November 16, 2012
    Publication date: June 20, 2013
    Applicant: CONOPCO, INC., D/B/A UNILEVER
    Inventor: CONOPCO, INC., D/B/A UNILEVER
  • Publication number: 20130158015
    Abstract: Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.
    Type: Application
    Filed: February 15, 2013
    Publication date: June 20, 2013
    Applicant: AERIE PHARMACEUTICALS, INC.
    Inventor: Aerie Pharmaceuticals, Inc.
  • Publication number: 20130150443
    Abstract: The present invention relates to a novel use of compounds having the general formula (I): CH3(—CH?CH)n—R??(I) where n=from 2 to 7, and R is chosen from among: CHO, CH2OH, CH2O—CO—R?, CO—OR?, CO—O(-), where R? is chosen from among H, the alkyl from C1 to C22, each compound of general formula (I) being used as such or in a mixture, as an active principle in a pharmaceutical or cosmetic composition to improve the human epidermal cell repair activity by means of the production of keratin mediated by the cytokeratins cK-19.
    Type: Application
    Filed: February 6, 2013
    Publication date: June 13, 2013
    Applicant: GIULIANI S.P.A.
    Inventors: Giammaria GIULIANI, Anna BENEDUSI, Sergio BARONI
  • Publication number: 20130150432
    Abstract: Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.
    Type: Application
    Filed: June 22, 2011
    Publication date: June 13, 2013
    Applicants: NORTHEAST OHIO MEDICAL UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Charles K Thodeti, Donald E. Ingber
  • Patent number: 8461201
    Abstract: The invention features methods for the preparation of naturally occurring trihydroxy polyunsaturated eicosanoids and their structural analogs. The invention further provides new derivatives and analogs of trihydroxy polyunsaturated eicosanoids that can be prepared according to these methods. The invention also provides compositions and methods using trihydroxy polyunsaturated eicosanoid derivatives for the prevention, amelioration and treatment of a variety of diseases or conditions associated with inflammation or inflammatory response, autoimmune diseases, rheumatoid arthritis, cardiovascular diseases, or abnormal cell proliferation or cancer.
    Type: Grant
    Filed: March 7, 2011
    Date of Patent: June 11, 2013
    Assignee: University of Southern California
    Inventor: Nicos A. Petasis
  • Publication number: 20130142845
    Abstract: The present invention is concerned with the use of combinations of opioid agonists and antagonists for treating Crohn's disease.
    Type: Application
    Filed: January 30, 2013
    Publication date: June 6, 2013
    Applicant: Euro-Celtique S.A.
    Inventor: Euro-Celtique S.A.